The Effect of Topical Sunscreen Plus Antioxidant Against the Visible Light Biological Effects
15. februar 2022 oppdatert av: Iltefat Hamzavi, Henry Ford Health System
Visible light is known to induce pigmentation in darker skin types.
The investigators aim to study the effects of visible light on the skin after topical application of sunscreen plus antioxidant.
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Faktiske)
32
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Michigan
-
Detroit, Michigan, Forente stater, 48202
- Henry Ford Hospital
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Patient age 18 and older
- Patients Fitzpatrick skin phototype IV-VI
- Patient able to understand requirements of the study and risks involved
- Patient able to sign a consent form
Exclusion Criteria:
- A recent history of vitiligo, melasma, and other disorders of pigmentation with the exception of post inflammatory hyperpigmentation
- A known history of photodermatoses
- A known history of melanoma or non-melanoma skin cancers
- Those planning on going to the tanning parlors
- Using any of the photosensitizing medication within the visible light range or additional medications at the discretion of the investigator (examples include (but not limited to) thiazide diuretics, regular use of NSAIDs, hydroxychloroquine, or voriconazole)
- A woman who is lactating, pregnant, or planning to become pregnant
- Patient planning on exposing the irradiated or control areas to the sun
- known allergy to anesthetics (lidocaine or epinephrine)
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Sunscreen application
All subjects will undergo topical application of 3 products and an additional site will serve as a control
|
topical application sunscreen containing topical antioxidants and sunscreen filters
topical application of product A without topical antioxidants
Topical application of antioxidants only
No product applied
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
diffuse reflectance spectroscopy
Tidsramme: Baseline- immediately after irradiation to assess immediate pigment darkening
|
Diffuse reflectance spectroscopy is a non-invasive objective measure of pigmentation based on reflectance patterns of the irradiated skin
|
Baseline- immediately after irradiation to assess immediate pigment darkening
|
|
photography
Tidsramme: Baseline-immediately after irradiation to assess immediate pigment darkening
|
Cross polarized photography is used to document pigmentation non-invasively and reduce surface glare of the skin.
|
Baseline-immediately after irradiation to assess immediate pigment darkening
|
|
investigator's global assessment score
Tidsramme: Baseline- Immediately after irradiation to assess immediate pigment darkening
|
The investigator's global assessment score is a non-invasive subjective measure of pigmentation in which investigators assign a value ranging between 0, corresponding with no hyperpigmentation, to 5, or severe or dark hyperpigmentation.
|
Baseline- Immediately after irradiation to assess immediate pigment darkening
|
|
Diffuse reflectance spectroscopy
Tidsramme: 24 hours after irradiation to assess persistent pigment darkening
|
Diffuse reflectance spectroscopy is a non-invasive objective measure of pigmentation based on reflectance patterns of the irradiated skin
|
24 hours after irradiation to assess persistent pigment darkening
|
|
photography
Tidsramme: 24 hours after irradiation to assess persistent pigment darkening
|
Cross polarized photography is used to document pigmentation non-invasively and reduce surface glare of the skin.
|
24 hours after irradiation to assess persistent pigment darkening
|
|
Investigator's global assessment score
Tidsramme: 24 hours after irradiation to assess persistent pigment darkening
|
The investigator's global assessment score is a non-invasive subjective measure of pigmentation in which investigators assign a value ranging between 0, corresponding with no hyperpigmentation, to 5, or severe or dark hyperpigmentation.
|
24 hours after irradiation to assess persistent pigment darkening
|
|
Diffuse reflectance spectroscopy
Tidsramme: 7 days after irradiation to assess delayed tanning
|
Diffuse reflectance spectroscopy is a non-invasive objective measure of pigmentation based on reflectance patterns of the irradiated skin
|
7 days after irradiation to assess delayed tanning
|
|
Photography
Tidsramme: 7 days after irradiation to assess delayed tanning
|
Cross polarized photography is used to document pigmentation non-invasively and reduce surface glare of the skin.
|
7 days after irradiation to assess delayed tanning
|
|
Investigator global assessment score
Tidsramme: 7 days after irradiation to assess delayed tanning
|
The investigator's global assessment score is a non-invasive subjective measure of pigmentation in which investigators assign a value ranging between 0, corresponding with no hyperpigmentation, to 5, or severe or dark hyperpigmentation.
|
7 days after irradiation to assess delayed tanning
|
|
Biological effects
Tidsramme: 24 hours after irradiation
|
biopsy with melanocyte and melanin stains to assess pigmentation
|
24 hours after irradiation
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Iltefat Hamzavi, MD, Henry Ford Hospital
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Generelle publikasjoner
- Mahmoud BH, Ruvolo E, Hexsel CL, Liu Y, Owen MR, Kollias N, Lim HW, Hamzavi IH. Impact of long-wavelength UVA and visible light on melanocompetent skin. J Invest Dermatol. 2010 Aug;130(8):2092-7. doi: 10.1038/jid.2010.95. Epub 2010 Apr 22.
- Porges SB, Kaidbey KH, Grove GL. Quantification of visible light-induced melanogenesis in human skin. Photodermatol. 1988 Oct;5(5):197-200.
- Mahmoud BH, Hexsel CL, Hamzavi IH, Lim HW. Effects of visible light on the skin. Photochem Photobiol. 2008 Mar-Apr;84(2):450-62. doi: 10.1111/j.1751-1097.2007.00286.x. Epub 2008 Jan 29.
- Kollias N, Baqer A. An experimental study of the changes in pigmentation in human skin in vivo with visible and near infrared light. Photochem Photobiol. 1984 May;39(5):651-9. doi: 10.1111/j.1751-1097.1984.tb03905.x. No abstract available.
- Duteil L, Cardot-Leccia N, Queille-Roussel C, Maubert Y, Harmelin Y, Boukari F, Ambrosetti D, Lacour JP, Passeron T. Differences in visible light-induced pigmentation according to wavelengths: a clinical and histological study in comparison with UVB exposure. Pigment Cell Melanoma Res. 2014 Sep;27(5):822-6. doi: 10.1111/pcmr.12273. Epub 2014 Jul 25.
- Yakes FM, Van Houten B. Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress. Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):514-9. doi: 10.1073/pnas.94.2.514.
- Boukari F, Jourdan E, Fontas E, Montaudie H, Castela E, Lacour JP, Passeron T. Prevention of melasma relapses with sunscreen combining protection against UV and short wavelengths of visible light: a prospective randomized comparative trial. J Am Acad Dermatol. 2015 Jan;72(1):189-90.e1. doi: 10.1016/j.jaad.2014.08.023. Epub 2014 Oct 22. No abstract available.
- Wang SQ, Osterwalder U, Jung K. Ex vivo evaluation of radical sun protection factor in popular sunscreens with antioxidants. J Am Acad Dermatol. 2011 Sep;65(3):525-530. doi: 10.1016/j.jaad.2010.07.009. Epub 2011 May 31.
- Kunisada M, Sakumi K, Tominaga Y, Budiyanto A, Ueda M, Ichihashi M, Nakabeppu Y, Nishigori C. 8-Oxoguanine formation induced by chronic UVB exposure makes Ogg1 knockout mice susceptible to skin carcinogenesis. Cancer Res. 2005 Jul 15;65(14):6006-10. doi: 10.1158/0008-5472.CAN-05-0724.
- Herrling T, Jung K, Fuchs J. Measurements of UV-generated free radicals/reactive oxygen species (ROS) in skin. Spectrochim Acta A Mol Biomol Spectrosc. 2006 Mar 13;63(4):840-5. doi: 10.1016/j.saa.2005.10.013.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
13. mars 2018
Primær fullføring (Faktiske)
15. september 2018
Studiet fullført (Faktiske)
22. april 2019
Datoer for studieregistrering
Først innsendt
30. januar 2017
Først innsendt som oppfylte QC-kriteriene
22. februar 2017
Først lagt ut (Faktiske)
28. februar 2017
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
2. mars 2022
Siste oppdatering sendt inn som oppfylte QC-kriteriene
15. februar 2022
Sist bekreftet
1. februar 2022
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- IRB # 9695
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Nei
IPD-planbeskrivelse
No individual participant data will be available to other researchers.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .